Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)

The treatment of non-nasopharyngeal SCCHN is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally advanced setting, surgery with curative intent has been the standard of care; however, the recent approval of Keytruda (Merck & Co.), supported by positive outcomes in KEYNOTE-689, introduces a novel potential approach for appropriately selected patients. In the recurrent or metastatic setting, EGFR inhibition with Erbitux (Eli Lilly) was historically a systemic option. In patients with PD-L1–expressing tumors, immune checkpoint inhibitors, including Keytruda and Opdivo (BMS), along with their subcutaneous formulations (Keytruda Qlex and Opdivo Qvantig), are more frequently prescribed. This report evaluates the critical determinants influencing medical oncologists’ prescribing choices in the treatment of non-nasopharyngeal SCCHN.

Questions answered

• What are the current treatment practices in locoregionally advanced and recurrent or metastatic non-nasopharyngeal SCCHN, and which clinical factors influence treatment selection?
• What is the uptake of immune checkpoint inhibitors versus EGFR-targeted therapies in non-nasopharyngeal SCCHN, and how does this differ from PD-L1 CPS?
• What are the treatment rates for non-nasopharyngeal?
• What are the key drivers and constraints influencing the use of immune checkpoint inhibitors and EGFR-targeted therapies in unresectable or metastatic SCCHN?

Product Description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 100 U.S. medical oncologists

Key drugs covered: Erbitux; Keytruda; Keytruda Qlex; Opdivo; Opdivo Qvantig